Cargando…
The Potential of Methocinnamox as a Future Treatment for Opioid Use Disorder: A Narrative Review
The opioid epidemic is an ongoing public health crisis, and the United States health system is overwhelmed with increasing numbers of opioid-related overdoses. Methocinnamox (MCAM) is a novel mu opioid receptor antagonist with an extended duration of action. MCAM has potential to reduce the burden o...
Autores principales: | Jordan, Colleen G., Kennalley, Amy L., Roberts, Alivia L., Nemes, Kaitlyn M., Dolma, Tenzing, Piper, Brian J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149874/ https://www.ncbi.nlm.nih.gov/pubmed/35645327 http://dx.doi.org/10.3390/pharmacy10030048 |
Ejemplares similares
-
Long‐term antagonism and allosteric regulation of mu opioid receptors by the novel ligand, methocinnamox
por: Zamora, Joshua C., et al.
Publicado: (2021) -
Dynamic changes in methadone utilisation for opioid use disorder treatment: a retrospective observational study during the COVID-19 pandemic
por: Kennalley, Amy L, et al.
Publicado: (2023) -
Examination of methadone involved overdoses during the COVID-19 pandemic()
por: Kaufman, Daniel E., et al.
Publicado: (2023) -
Opioid Use Disorder Education for Students and the Future of Opioid Overdose Treatment
por: Balapal, Neha, et al.
Publicado: (2022) -
Prescription stimulant use during long-term opioid therapy and risk for opioid use disorder
por: Scherrer, Jeffrey F., et al.
Publicado: (2022)